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To compare effectiveness, associated cost of outcomes and cost-effectiveness of a
single annual infusion of zoledronic acid versus current treatment strategies plans
for postmenopausal osteoporosis in France.
METHODS:
Twelve simulation-based models were built to investigate three types of fractures:
vertebral (VF), non-vertebral excluding hip (NVF) and hip (HF), comparing two
groups: zoledronic acid and current postmenopausal antiosteoporotic treatment
strategies. Two effectiveness comparability assumptions have been tested: specific
agent efficacy values, and same standard efficacy values for all active agents. Direct
medical costs included drug costs, medical visits, monitoring and fracture
management. Adherence levels were integrated into the model under the
assumption that non-adherent patients had treatment effects similar to the levels of
placebo effectiveness.
RESULTS:
Using the most conservative assumption (same standard efficacy values for all active
agents), zoledronic acid strategy results in less vertebral, non-vertebral and hip
fractures than other current antiosteoporotic treatment options over 3 years:
12.04% vs. 14.18%, 10.61% vs. 11.28% and 2.82% vs. 4.64% respectively, (p<0.001).
In addition, zoledronic acid is more cost-effective than the current treatment
strategies in all types of fractures (p<0.001): 1497 euros vs. 1685 euros per VF
avoided, 1337 euros vs. 1404 euros per NVF avoided and 1216 euros vs. 1323 euros
per HF avoided.
CONCLUSION:
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